Justin Hewlett, MD
Pulmonary Disease · Nashville, TNNPI 1063778231
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $8,240 of the $9,574 with a category attached, or 86.1%. Boehringer Ingelheim accounts for 98.2% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2023 at $8,431 and has fallen 99.8% since, to $13 in 2024.
Across 10 payments — averaging $957.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$9K
- Genentech USA, Inc.$125
- Medtronic$29
- Insmed, Inc.$16
Across 151 payments — averaging $2506.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$188K
- Boehringer Ingelheim$185K
- Boehringer Ingelheim International GmbH$5K
What the payments were for
- Consulting fees$8,24086%
- Travel & lodging$1,08911%
- Food & beverage$2292%
- Education$160%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 6 | $9,404 |
| Genentech USA, Inc. | 1 | $125 |
| Medtronic | 2 | $29 |
| Insmed, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,574 in reported general payments places this provider in the 70th percentile of 339 pulmonary disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 118 | $1,453,144 |
| Humira(Cf) PenAdalimumab | 25 | $264,504 |
| NucalaMepolizumab | 25 | $180,629 |
| Dupixent PenDupilumab | 17 | $58,694 |
| Pirfenidone | 16 | $58,277 |
| Breo ElliptaFluticasone/Vilanterol | 38 | $21,610 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $15,140 |
| Sirolimus | 23 | $11,035 |
| Mycophenolate Mofetil | 41 | $7,027 |
| Advair HfaFluticasone Propion/Salmeterol | 14 | $6,798 |
| DuleraMometasone/Formoterol | 12 | $4,104 |
| Hydroxychloroquine Sulfate | 13 | $1,316 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 30 | $1,041 |
| Prednisone | 80 | $778 |
| Ipratropium Bromide | 24 | $766 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev | $9,404 | $1,453,144118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 339 pulmonary disease providers in Tennessee.
Other pulmonary disease in Nashville
- Lisa LancasterNashville$519K
- Otis RickmanNashville$392K
- Susan GarwoodNashville$343K
- Joao DeandradeNashville$245K
- Anna HemnesNashville$183K
- Bryan HayNashville$126K
- Karl KuhnNashville$106K
- Fabien MaldonadoNashville$83K
- Margaret SalisburyNashville$53K
- Victor KhaNashville$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.